The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

Hims and Hers (NYSE:HIMS) shares rose 10% Tuesday, adding to Monday’s 49% gain following analyst upgrades after the company announced a collaboration with Novo ...

Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs, ...

Danish pharmaceutical leader Novo Nordisk has transformed a legal confrontation with the telemedicine provider Hims & Hers into a collaborative venture. The ...

Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the telehealth ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

BLKBRD Asset Management exited 318,666 shares of Hims & Hers Health; estimated trade size $18.07 million, based on quarterly average pricing. Quarter-end position value dropped by $18.07 million, ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 ...

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.

Three health-technology names are drawing fresh analyst attention as strategic partnerships and business pivots reframe their risk-reward profiles.

Hims & Hers Health Inc HIMS shares are rising higher on Tuesday. Multiple analysts upgraded the stock following the company’s deal with Novo Nordisk this week. Hims & Hers has struck a new agreement ...

Hims & Hers Health has sparred with Novo Nordisk for months over the Danish drugmaker’s refusal to sell weight-loss drugs on its platform, but the bitter feud appears to have reached its end.